Abstract: The present invention relates to a catalyst containing a vanadium-phosphorus oxide and an alkali metal, wherein the proportion by weight of alkali metal in the vanadium-phosphorus oxide is in the range from 10 to 400 ppm, based on the total weight of the vanadium-phosphorus oxide, a process for producing it and also the use of the catalyst for the gas-phase oxidation of hydrocarbons, in particular for preparing maleic anhydride.

Abstract: The present invention relates to a catalyst containing a vanadium-phosphorus oxide and an alkali metal, wherein the proportion by weight of alkali metal in the vanadium-phosphorus oxide is in the range from 10 to 400 ppm, based on the total weight of the vanadium-phosphorus oxide, a process for producing it and also the use of the catalyst for the gas-phase oxidation of hydrocarbons, in particular for preparing maleic anhydride.

Abstract: The use of a compound having a gon-4-ene nucleus, said nucleus having attached thereto, in the 13 position, a polycarbon-alkyl radical having 2 to about 16 carbon atoms, said compound containing at least 19 and up to 40 carbon atoms in its carbon-carbon skeleton, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells.

Abstract: The use of a compound of general formula (I): or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells, wherein: R1 is a alkoxy, alkyl, ether or ester group; R2 is H or has the formula wherein Y is linear or branched, saturated or unsaturated, aliphatic group with from 2 to 23 carbon atoms, or a cyclic group, and which can contain substituents selected from the group consisting of hydroxyl, alkoxy, amino, carboxyl, cyano, nitro, alkylsuphonyl or halogen atoms, X is O or S; and R3 is any substituent.